Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: There is continuing debate about the net benefits of population screening for type 2 diabetes. We compared the risk of cardiovascular disease (CVD) and mortality among incident cases of type 2 diabetes in a screened group with those in an unscreened group. METHODS: In this register-based non-randomised controlled trial, eligible individuals were all men and women aged 40-69 years without known diabetes, registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes-risk-score questionnaire. Individuals at moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075), and compared risk of CVD and mortality in these groups between 2001 and 2012. RESULTS: In the screening group, 27,177/153,107 (18%) individuals attended for screening, of whom 1533 were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Between 2001 and 2012, the risks of CVD and mortality were lower among individuals with diabetes in the screening group compared with individuals with diabetes in the no-screening (control) group (CVD HR 0.84, 95% CI 0.80, 0.89; mortality HR 0.79, 95% CI 0.74, 0.84). CONCLUSIONS/INTERPRETATION: A single round of diabetes screening and cardiovascular risk assessment in middle-aged Danish adults in general practice was associated with a significant reduction in risk of all-cause mortality and CVD events in those diagnosed with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A study from Denmark [75] found that a single round of diabetes screening and cardiovascular risk assessment in middle-aged adults in general practice was associated with a significant reduction in risk of all-cause mortality and CVD events in people with T2DM.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 1×
“General practitioners were encouraged to calculate the European Heart SCORE [17] during the appointment, to inform individuals about their score and provide appropriate advice and treatment to those at high risk.”
Background(1967) · Project Euclid (Cornell University) · Cited by 4,720
Proceedings of the fifth Berkeley symposium on mathematical statistics and probability.
Kojima, K.-I. (1969) · Europe PMC (PubMed Central) · Cited by 3,648
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306 · cited 2×
“One argument for considering screening for type 2 diabetes is the historical observation [22] that there is an extended latent or pre-clinical phase (lead time) inwhich people could be diagnosed and during which earlier treatment might have a beneficial longterm effect.”
BackgroundResultScreening for type 2 diabetes.
Engelgau, M. M., Narayan, K. M., & Herman, W. H. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1563 · Cited by 1,027
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · cited 4×
“Screening programme Full details of the programme have been reported [11, 12, 14].”
BackgroundMethodResultInfluentialSelf-citationHerman, W. H., Ye, W., Griffin, S. J., Simmons, R. K., Davies, M. J., Khunti, K., Rutten, G. E. H. M., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2459 · Cited by 340 · cited 2×
“As such, we cannot directly observe the magnitude of cardiovascular risk reduction that might occur among individuals with diabetes found by screening compared with those with no screening and hence no treatment until the time of clinical diagnosis [5].”
BackgroundSelf-citationA Danish Diabetes Risk Score for Targeted Screening
Glümer, C., Carstensen, B., Sandbæk, A., Lauritzen, T., Jørgensen, T., & Borch-Johnsen, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.727 · Cited by 324 · cited 1×
“Eligible individuals registered with the 181 practices who agreed to take part were sent a diabetes-risk-score questionnaire, [15, 16] with an invitation to visit their general practitioners for a diabetes test and a cardiovascular risk assessment if they scored ≥5 (maximum 15) points or were invited when visiting the…”
BackgroundSelf-citationSiu, A. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m15-2345 · Cited by 319 · cited 1×
“proposed or introduced in a number of countries [8, 9].”
BackgroundThe Danish National Diabetes Register: trends in incidence, prevalence and mortality
Carstensen, B., Kristensen, J. K., Ottosen, P., Borch-Johnsen, K., & on behalf of the steering group of the National Diabetes Register (2008) · Diabetologia · doi:10.1007/s00125-008-1156-z · Cited by 311
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Simmons, R. K., Echouffo-Tcheugui, J. B., Sharp, S. J., Sargeant, L. A., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61422-6 · Cited by 252 · cited 2×
“However, trials of population-based screening for type 2 diabetes [10] and related cardiovascular risk factors [11] have”
BackgroundSelf-citationGRuttenfor the ADDITION Study Group, Lauritzen, T., Griffin, S., Borch-Johnsen, K., Wareham, N., & Wolffenbuttel, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801420 · Cited by 249 · cited 3×
“Screening programme Full details of the programme have been reported [11, 12, 14].”
BackgroundSelf-citationPutting prevention first - vascular checks: risk assessment and management
Young, H. (2010) · Cited by 160
Porta, M., Curletto, G., Cipullo, D., Rigault de la Longrais, R., Trento, M., Passera, P., Taulaigo, A. V., Di Miceli, S., Cenci, A., Dalmasso, P., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2101 · Cited by 138
Eborall, H. C., Griffin, S. J., Prevost, A. T., Kinmonth, A.-L., French, D. P., & Sutton, S. (2007) · BMJ · doi:10.1136/bmj.39303.723449.55 · Cited by 137 · cited 1×
“Screening and early treatment for diabetes appear to be associatedwith limited harms [6, 7].”
BackgroundSelf-citationWhy cancer screening has never been shown to “save lives”—and what we can do about it
Prasad, V., Lenzer, J., & Newman, D. H. (2016) · BMJ · doi:10.1136/bmj.h6080 · Cited by 137
Christensen, J. O., Sandb�k, A., Lauritzen, T., & Borch‐Johnsen, K. (2004) · Diabetologia · doi:10.1007/s00125-004-1496-2 · Cited by 101 · cited 2×
“Eligible individuals registered with the 181 practices who agreed to take part were sent a diabetes-risk-score questionnaire, [15, 16] with an invitation to visit their general practitioners for a diabetes test and a cardiovascular risk assessment if they scored ≥5 (maximum 15) points or were invited when visiting the…”
BackgroundSelf-citationValidation of the Danish National Diabetes Register
Green, A., Sortsø, C., Jensen, P. B., & Emneus, M. (2014) · Clinical Epidemiology · doi:10.2147/clep.s72768 · Cited by 69
The psychological impact of screening for type 2 diabetes
Adriaanse, M. C., & Snoek, F. J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.590 · Cited by 62 · cited 1×
“Screening and early treatment for diabetes appear to be associatedwith limited harms [6, 7].”
BackgroundKuo, H. S., Chang, H., Chou, P., Teng, L. Y., & Chen, T. H. (1999) · International Journal of Epidemiology · doi:10.1093/ije/28.2.233 · Cited by 59
Rahman, M., Simmons, R. K., Hennings, S., Wareham, N. J., & Griffin, S. J. (2012) · Diabetologia · doi:10.1007/s00125-011-2441-9 · Cited by 56
Self-citationSimmons, R. K., Griffin, S. J., Witte, D. R., Borch-Johnsen, K., Lauritzen, T., & Sandbæk, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4323-2 · Cited by 51
Self-citationStatins anticancer targeted delivery systems: re-purposing an old molecule
Safwat, S., Ishak, R. A., Hathout, R. M., & Mortada, N. D. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12707 · Cited by 48 · cited 1×
“We also observed lower rates of cancer incidence in the screening group, which might be linked to changes in health behaviour and prescribing [26].”
BackgroundA Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
Schuetz, C. A., Alperin, P., Guda, S., van Herick, A., Cariou, B., Eddy, D. M., Gumprecht, J., Nicolucci, A., Schwarz, P. E. H., Wareham, N. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066454 · Cited by 47
Chang, H.-J., Kuo, H., Tung, T., Chou, P., & Chen, T. H.-H. (2000) · Preventive Medicine · doi:10.1006/pmed.2000.0728 · Cited by 15
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · cited 1×
“WHO 1999 criteria were used to diagnose diabetes [18], including the requirement for a confirmatory test on another day.”
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
“3 Novo Nordisk A/S, Søborg, Denmark.”
BackgroundInfluentialKaptoge, S., Seshasai, S., Sun, L., Walker, M., Bolton, T., Spackman, S., Ataklte, F., Willeit, P., Bell, S., Burgess, S., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00223-1 · Cited by 231
“Adjusted HR (95% CI)”
Self-citationOverdiagnosis in primary care: framing the problem and finding solutions
Kale, M. S., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k2820 · Cited by 165
The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps
Thomas, B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1133-6 · Cited by 174
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 215
Metadata
- Authors
- Simmons, R. K., Griffin, S. J., Lauritzen, T., & Sandbæk, A.
- Affiliations
- Aarhus University (DK)
- Corresponding author
- Simmons, Rebecca K.
- Venue
- Diabetologia
- Published
- 2017-08-23
- Volume
- 60
- Issue
- 11
- Pages
- 2192-2199
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6108415
- OpenAlex
- W2749360885
- Cited by
- 69
- References
- 27
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 3 · 2021: 7 · 2020: 12 · 2019: 8 · 2018: 9 · 2017: 4
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Pfizer
- GlaxoSmithKline
- Strategiske Forskningsråd
- Aarhus Universitet
- Sundhed og Sygdom, Det Frie Forskningsråd
- National Institute for Health and Care Research (NF-SI-0515-10119)
- Aarhus Universitets Forskningsfond
- Novo Nordisk
- Servier
- Medical Research Council (MC_UU_12015/4)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes screening, cardiovascular disease, mortality, newly diagnosed diabetes, primary care screening, screening uptake, cardiovascular risk assessment
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Denmark, Diabetes Mellitus, Type 2, Female, Humans, Male, Mass Screening, Middle Aged, Primary Health Care, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.